Pharma Intermediates and CDMO Custom Synthesis

Abstract

This report covers the highest-value downstream of fine chemicals: pharma intermediates and custom synthesis (CDMO). It spans innovator intermediates, specialty APIs, peptide and oligonucleotide building blocks, and pharmaceutical excipients, and analyses the changing split between captive and merchant production.

The central judgement is that the moat has moved from capacity to quality systems and process development. Being selected as a supplier during early clinical phases locks in commercial-scale volume later, which makes the front-end process team more decisive than back-end reactor volume.

Key findings

• Pharmaceuticals and nutraceuticals are the largest fine chemicals downstream, at roughly 38% of the global market.
• Rising molecular complexity keeps pushing outsourcing ratios higher, steadily expanding CDMO volume.
• Captive production still holds around 60% share, but merchant sourcing grows faster on new modalities and capacity flexibility.
• New modalities such as peptides and oligonucleotides create structural demand for high-purity building blocks and dedicated capacity.
• Supplier selection is strongly path-dependent: switching an early-clinical supplier at commercial scale is prohibitively costly.
• Quality systems, EHS records and audit pass rates are harder gates than capacity.